

CURRICULUM VITAE ABREVIADO (CVA)

IMPORTANT – The Curriculum Vitae cannot exceed 4 pages. Instructions to fill this document are available in the website.

Part A. PERSONAL INFORMATION

First name	María del Mar		
Family name	Malagón Poyato		
Gender (*)		Birth date	
Social Security, Passport, ID number			
e-mail		URL Web	
Open Researcher and Contributor ID (ORCID) (*)			

(*) *Mandatory*

A.1. Current position

Position	Full Professor		
Initial date	26/06/2008		
Institution	University of Córdoba		
Department/Center	Dept. of Cell Biology, Physiology and Immunology	Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Universidad de Córdoba/ Hospital Universitario Reina Sofía	
Country	Spain	Teleph. No.	
Key words	Adipose Tissue, Lipid metabolism, Adipokines, Fibrosis, Obesity, Insulin Resistance, 3D cellular models, Proteomics		

A.2. Previous positions (research activity interruptions, indicate total months)

Period	Position/Institution/Country/Interruption cause
1999-2008	Associate Professor/University of Córdoba
1993-1999	Assistant Professor/University of Córdoba
1990-1993	Postdoctoral Researcher/University of Rouen (France)
1986-1989	Predoctoral Researcher/University of Córdoba

A.3. Education

PhD, Licensed, Graduate	University/Country	Year
PhD in Biological Sciences	University of Cordoba	1990
Degree in Biological Sciences	University of Cordoba	1985

Part B. CV SUMMARY (max. 5000 characters, including spaces)

General quality indicators of scientific research

6-Yr Research Periods: 5 (Last: 01-01-2017);
 Total PhD Thesis: 23 (9 presented from 2013, 5 ongoing); Total Times Cited: 5424 (WoS), 5660 (Scopus); Times Cited (2013-2022/10 years): 3904 (390/year) (WoS/Publons); Total Times Cited/Cites per year (2018-2022/5 years): 2231 (446/year) (WoS/Publons); Total Publications (original articles&reviews): 186; Total Q1 Publications (including D1)/Total Publications from 2013: 60/76; H-Index: 42 (Researcher ID), 43 (Scopus).

Prof. María M. Malagón leads the research group “Metabolism and Adipocyte Differentiation” at the Maimonides Biomedical Research Institute of Córdoba (IMIBIC; Córdoba, Spain). She was appointed as Deputy Scientific Director of the IMIBIC in 2019, and coordinated IMIBIC’s Research Programme of Nutrition, Endocrine and Metabolic Diseases in 2016-2019 and the Training Committee 2016-2018, when she was also the president of the Ph.D. Programme on Biomedicine of the University of Córdoba. With 186 scientific publications in total (WoS) and over 76 since 2013, Prof. Malagón has considerable experience in the field of adipose tissue



biology and pathophysiology. She belongs to the National Network on Pathophysiology of Obesity and Nutrition (CIBERObn). She has been awarded 8 national grants and 1 Retos-Colaboración (Empresa) (Plan Nacional), 2 Collaborative France-Spain grants (Ministry of Science and Education, Spain), as well as 4 Excellence grants (Consejería de Economía, Innovación, Ciencia y Empleo) and 1 research grant of the Consejería de Salud y Bienestar Social (Junta de Andalucía, Spain). Prof Malagón has supervised 23 Ph.D. Thesis and numerous Master and Degree Projects (5 and 10, respectively, from 2019). She has 2 patents and 1 additional under review. She was Chair of the Integrative Biology and Physiology (BFI) review Committee of the General Subdirectorate for Research Projects of the Ministry of Economy and Competitiveness (2010-2014), and Member of the National Agency of Evaluation (ANEP, "Physiology and Pharmacology"), Spanish Ministry of Science, 2004-2009). She is member of numerous review panels (Miguel Servet, Ramón y Cajal, Sara Borrell, and Juan de la Cierva programs, Miguel Servet, Nicolas Monardes, L'Oreal Grants), and has been appointed as auditor for Biomedical Research Institutes for the National Institute of Health (ISCIII; from 2018) and evaluator of Research Groups for the Spanish National Research Council (CSIC, 2018). She is member of the Technical Committee of Evaluation and Accreditation of the Andalusian Agency of Knowledge (DEVA; 2014-present) and Castilla and Leon Agency of Knowledge (ACSUCyL, 2017-2021). She has been Council Member of the Foundation of the Spanish Society of Endocrinology and Nutrition (SEEN) (2011-2017), Chair of the Spanish Society for the Study of Obesity (SEEDO; 2014-2017), and Treasurer and Member of the Scientific Council of the Spanish Society of Cell Biology (2001-2011). She has coordinated the Working group on Translational Research of the SEEDO and acted as Vice-president of the SEEDO Foundation (2017-2022). On international level, she evaluates projects for ANR and AERES (France), NSF (USA), Research Grant Council of Hong Kong, Agencia Nacional de Promoción Científica y Tecnológica (FONCyT, Argentina), Research Institutes of Switzerland y Austrian Science Fund (FWF) and has participated in the Review Board of "Personalized Health and Related Technologies (PHRT)" (Research Institutions in Switzerland). Prof Malagón serves as associated editor for *Frontiers in Neuroendocrine Sciences*, and have served as editor for *Endocrinology*, *Journal of Neuroendocrinology*, *General and Comparative Endocrinology* and *Journal of Integrated Omics*. She has been Council Member of the International Federation of Comparative Endocrinology Societies (2011-2005) and the Société de Neuroendocrinologie (France) (2006-2009) and Member of the Scientific Advisory Board of the International Regulatory Peptide Society (2008-2014). She has been a member of the organizing committee for international and national meetings (e.g., European Congress of Endocrinology, SEEN, SEEDO, SECO, SEBC). She is member of the Sounding board of Taxonomy of Obesity as an NCD Initiative from EASO (European Association for the Study of Obesity). In 2018, she was awarded the SEEN Prize for her Professional Career. She is President of the Spanish Society of Obesity (SEEDO; from 2022). Prof. Malagón regularly performs research dissemination activities, including participation in Researchers' Night and interviews in the media (TV, radio and press).

A selection of articles and projects from the last 10 years, and invited conferences from the last 5 years are presented.

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications (see instructions)

1. Navarro-Ruiz MDC et al. (9*/10*). Understanding the adipose tissue acetylome in obesity and insulin resistance. *Transl Res.* 2022;246:15-32. doi: 10.1016/j.trsl.2022.02.008. IF: 10,171 (D1). ***AC**
2. Sánchez-Ceinos et al. Impaired mRNA splicing and proteostasis in preadipocytes in obesity-related metabolic disease. *Elife.* 2021 Sep 21;10:e65996. doi: 10.7554/eLife.65996. IF: 8,146 (D1). **AC**
3. Sánchez-Ceinos et al. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction preceding type 2 diabetes onset. *Mol Ther Nucleic Acids.* 2021 Jan 20;23:1035-1052. doi: 10.1016/j.omtn.2021.01.014. IF: 8,886 (D1). **AC**

4. Fernández-Vega et al. Optimization of a MALDI-Imaging protocol for studying adipose tissue-associated Disorders. *Talanta*. 2020. 219:121184. doi: 10.1016/j.talanta.2020.121184. IF: 4,916 (Q1). **AC**
5. Guzmán-Ruiz et al. Adipose tissue depot-specific intracellular and extracellular cues contributing to insulin resistance in obese individuals. *FASEB J*. 2020. 34(6):7520-7539. doi: 10.1096/fj.201902703R. IF: 5,391 (D1). **AC**
6. Moreno-Castellanos et al. The cytoskeletal protein septin 11 is associated with human obesity and is involved in adipocyte lipid storage and metabolism. *Diabetologia*. 2017; 60(2):324-335. doi: 10.1007/s00125-016-4155-5. IF: 7,113 (D1). **AC**
7. El Bekay R et al. (15*/16*). Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. *Br J Pharmacol*. 2016;173(11):1820-34. doi: 10.1111/bph.13481. PMID: 26993859. IF: 8,74 (D1). ***AC**
8. Díaz-Ruiz et al. Proteasome Dysfunction Associated to Oxidative Stress and Proteotoxicity in Adipocytes Compromises Insulin Sensitivity in Human Obesity. *Antioxid Redox Signal*. 2015; 23(7):597-612. doi: 10.1089/ars.2014.5939. IF: 7.407 (D1). **AC**
9. R Guzmán-Ruiz et al. (15/15). Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β -cells. 2014. *Int J Obesity*. 38-12, pp.1545-1554. doi: 10.1038/ijo.2014.36. IF: 5,004 (Q1). **AC**
10. Kulkarni et al. Use of a fibrin-based system for enhancing angiogenesis and modulating inflammation in the treatment of hyperglycemic wounds. *Biomaterials* 2014;35:2001-10. doi: 10.1016/j.biomaterials. IF: 8.312 (D1). (9/10 authors; PI of the biological work).

C.2. Congress, indicating the modality of their participation (invited conference, oral presentation, poster)- **Invited Conferences from 2018**

1. MM Malagón. Investigación Traslacional. Actualización Científica. Annual Obesity Meetings (AOM, 3rd Edition). 2023. Madrid.
2. MM Malagón. Adipobiology at the Crossroad of Obesity Research. European Association for the Study of Obesity (EASO) COMs Summit/Best of ECO. 2022. Estambul, Turkey.
3. MM Malagón. Epidemiología y situación de la obesidad en España. XVIII Congreso de la Sociedad Española de Obesidad (SEEDO). 2022. Barcelona.
4. MM Malagón. Gestión de la Ciencia. Foro Desarrollo Profesional para jóvenes investigadores. 44^o Congreso de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM). 2022. Málaga.
5. MM Malagón. Obesidad como enfermedad:¿qué factores contribuyen a su (des)-control?. Seminarios de la Sociedad Española de Arteriosclerosis (SEA). 2022. Online.
6. MM Malagón. A Journey to the adipocyte core. XIX Congreso de la Sociedad Española de Biología Celular (SEBC). 2021. Boadilla del Monte, Madrid.
7. MM Malagón. Avances en investigación traslacional en obesidad. 62^o Congreso Sociedad Española de Endocrinología y Nutrición (SEEN). Sociedad Española de Endocrinología y Nutrición (SEEN). 2021.
8. MM Malagón. Investigación Traslacional. Lo más destacado - Congresos 2021. Annual Obesity Meetings (AOM 2nd Edition). 2021. Madrid.
9. MM Malagón. Investigación Traslacional en Obesidad en 2020. Annual Obesity Meetings (AOM 1st Edition). 2020. Online.
10. MM Malagón. ¿Qué sabemos de la disfunción del tejido adiposo en la diabetes?. Diabetes 2020. SEEN/SEEDO/SED. 2020. Online.
11. MM Malagón. Septins and its role on adipocyte pathophysiology and insulin resistance. 52nd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI). 2018. Barcelona.
12. MM Malagón. What fat does with your pituitary. 20th European Congress of Endocrinology. European Society of Endocrinology (ECE). 2018. Barcelona.

C.3. Research projects, indicating your personal contribution.

1. UCO-202099901920128, Nuevos Retos y Abordajes Moleculares en Relación al Daño Fibrótico del Tejido Adiposo Asociado a Nuevos Fármacos. PROYECTOS DE I+D+i FEDER

ANDALUCÍA 2014-2020. Consejería de Transformación Economía, Industria, Conocimiento y Universidades. JJAA. 2021-2022. **PI**.

2. PID2019-108403-RB-100, Caracterización del matrisoma del tejido adiposo y papel de la remodelación de la matriz extracelular en la resistencia a insulina asociada a obesidad Proyectos de I+D+i, RETOS DE LA SOCIEDAD 2019, MICINN. 2020-2023. **PI**.

3. PY18-1761, Impacto de la Remodelación de la Matriz Extracelular Sobre la Plasticidad Celular en El Tejido Adiposo en Obesidad. Proyecto de Excelencia. Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía. 2020-2023. **PI**.

4. BFU2016-76711-R, Caracterización de componentes extracelulares e intracelulares que definen la expansión del tejido adiposo. Proyectos de I+D+i 2016, RETOS DE LA SOCIEDAD, MINECO. 2017-2019. **PI**.

5. BFU2017-90578-REDT y BFU2015-70454-REDT, Red Temática de Investigación sobre plasticidad adiposa y su impacto fisiopatológico ACCIONES DE DINAMIZACIÓN "REDES DE EXCELENCIA", 2015. MINECO. F Villarroja. 2016-2017/2017-2019. **PI** Hub Córdoba.

6. Next-generation RNA sequencing and single-cell RNAseq: Novel opportunities for understanding human adipose tissue pathophysiology and obesity Acciones Cooperativas Intramurales CIBEROBN. F Villarroja. 2017-2018. **PI** Hub Córdoba.

7. RTC-2016-4589-1, Integración de plataformas para la identificación de dianas terapéuticas y el desarrollo de nuevos productos para la prevención y/o tratamiento de la radiodermatitis. Innohealth. Convocatoria Retos-Colaboración 2016, MINECO. 2017-2018. **PI**.

8. PIE14/00005, Early predictors and causes of loss of phenotypic flexibility as individual risk factor of metabolic disease: towards a personalized medicine (FLEXI-MET). Integrated Projects of Excellence Call. 2014 (FIS/ISCIII). 2015-2017. **PI** of WP.

9. BFU-2013-44229-R, Caracterización de nuevas rutas reguladoras del metabolismo lipídico en adipocitos. Alteraciones en obesidad. Convocatoria de Retos 2014. MINECO. (IMIBIC/Universidad de Córdoba). 2014-2017. **PI**.

10. PI-0200-2013, Identificación de biomarcadores de disfunción del tejido adiposo en condiciones de resistencia a insulina Proyectos de Investigación. Consejería de Salud. Junta de Andalucía. (IMIBIC/Universidad de Córdoba). 2014-2016. **PI**.

C.4. Contracts, technological or transfer merits, Include patents and other industrial or intellectual property activities (contracts, licenses, agreements, etc.) in which you have collaborated. Indicate: a) the order of signature of authors; b) reference; c) title; d) priority countries; e) date; f) Entity and companies that exploit the patent or similar information, if any

1. J.P. Castaño; M.M. Malagón; F. Gracia-Navarro; S. García-Navarro; R. Vázquez-Martínez; A.J. Martínez-Fuentes; M. Durán-Prado. PCT/ES07/000627. Truncated Isoforms of Somatostatin Receptor-5 in Pituitary Tumors 17/04/2010. Universidad de Córdoba.

2. J.P. Castaño; M.M. Malagón; F. Gracia-Navarro; S. García-Navarro; R. Vázquez-Martínez; A.J. Martínez-Fuentes; M. Durán-Prado. P200502701. Isoformas del receptor de la somatostatina humano tipo 5 producidas por procesamiento alternativo y parejas de oligonucleótidos para su detección por PCR. España. 2005. Universidad de Córdoba.

3. R. Guzmán Ruiz, MM. Malagón, J. Sánchez-Ceinos, C. Tercero Alcázar, D. González Cano, PP. García Luna, JL. Pereira Cunill, S. Morales Conde. Búsqueda de biomarcadores predictivos de respuesta a cirugía bariátrica. Submitted. ID: 2022/76; Fecha de registro: 18/10/2022